IQVIA Holdings Inc. — Q1 2021 Form 10-Q
Reporting period: Three months ended March 31, 2021; unaudited. IQVIA provides analytics, technology and clinical research services to the life sciences industry through Technology & Analytics Solutions (TAS), Research & Development Solutions (R&D), and Contract Sales & Medical Solutions (CSMS).
Financial performance
- Revenue: $3.409 billion, up $655 million (23.8%) year over year; constant-currency growth was 21.4%. R&D revenue rose 29.6% to $1.868 billion, TAS rose 20.7% to $1.348 billion, and CSMS declined 1.5% to $193 million.
- Profit: Operating income was $342 million, versus $193 million; net income attributable to IQVIA was $212 million, versus $82 million. Diluted EPS was $1.09, versus $0.42.
- Margins: Operating margin was approximately 10.0%, compared with 7.0%. Costs of revenue were 67.3% of revenue, versus 66.2%; SG&A was 13.0%, versus 14.8%. Segment profit was $731 million, versus $547 million.
- Cash flow: Operating cash flow was $867 million, versus $163 million; investing cash outflow was $176 million, and financing cash outflow was $168 million. Cash increased by $491 million to $2.305 billion.
- Liquidity and debt: Current assets were $5.579 billion and current liabilities $4.868 billion. Total debt principal was $12.307 billion, excluding $1.5 billion available under the revolving credit facility; cash less debt was approximately $10.0 billion. The company reported compliance with material financial covenants and said available liquidity and expected cash flows should meet requirements for at least 12 months.
Material changes and notable items
- Revenue growth was led by R&D, including higher clinical services and lab testing volume and incremental work on large COVID-19 vaccine trials. TAS growth included real-world and analytical services and COVID-19-related work. Management attributed CSMS’s revenue decline mainly to lower Americas volume.
- R&D contracted backlog increased to $23.2 billion from $22.6 billion at year-end; approximately $6.5 billion was expected to convert to revenue over the next 12 months. Separately, remaining performance obligations were approximately $26.1 billion, with about 35% expected to be recognized over the next 12 months. These measures have different definitions.
- Operating cash flow improved substantially, driven principally by collections and higher unearned income, along with higher cash-related net income.
- On March 3, IQVIA issued €1.45 billion of senior notes at 1.750% due 2026 and 2.250% due 2029, using proceeds to redeem its 3.250% notes due 2025. The refinancing contributed to a $24 million debt-extinguishment loss.
- On April 1, after quarter-end, IQVIA acquired Quest Diagnostics’ 40% non-controlling interest in Q² Solutions for $760 million in cash, bringing ownership to 100%. The company expected lower non-controlling-interest deductions in future periods.
- Restructuring expense was $9 million; actions to streamline operations were expected to continue into 2022. The company repurchased 265,809 shares for $50.5 million during the quarter and had approximately $0.9 billion of authorization remaining.
Outlook, commentary and risks
The filing provides no consolidated revenue or earnings guidance. Management cited R&D backlog conversion as a key factor and stated that quarterly results are not necessarily indicative of full-year results. Risks highlighted include COVID-19 and other disruptions, contract termination or delays, backlog conversion, data access and privacy or cybersecurity issues, foreign exchange, regulation, competition and acquisition integration. Approximately 35% of first-quarter revenue was denominated in currencies other than the U.S. dollar. Management reported effective disclosure controls and no material change in internal control over financial reporting.
Investor verification points
- Assess whether COVID-related clinical trial and analytics demand is sustainable and how R&D costs and margins evolve as volumes change.
- Track backlog and remaining performance obligation conversion, noting their differing definitions and the timing of revenue recognition versus milestone-based invoicing.
- Review debt levels, refinancing effects, interest-rate and currency exposure, and liquidity after the $760 million Q² Solutions purchase.
- Monitor CSMS revenue trends, restructuring costs and execution, and the effect of full Q² Solutions ownership on earnings and cash flow.
- Separate recurring operating performance from the debt-extinguishment loss, foreign-exchange and investment gains, and other quarter-specific items.